



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/665,526	09/19/2003	Linda Owens Narhi	02-274-A	5581
20306	7590	04/19/2006	EXAMINER	
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP			XIE, XIAOZHEN	
300 S. WACKER DRIVE			ART UNIT	PAPER NUMBER
32ND FLOOR			1646	
CHICAGO, IL 60606			DATE MAILED: 04/19/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No.	Applicant(s)
	10/665,526	NARHI ET AL.
	Examiner	Art Unit
	Xiaozhen Xie	1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 22 March 2006.
- 2a) This action is FINAL.                            2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-4, 15-17 and 19-21 is/are pending in the application.
  - 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 1-4, 15-17 and 19-21 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on 9/19/2003 is/are: a) accepted or b) objected to by the Examiner.
 

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) All    b) Some \* c) None of:
    1. Certified copies of the priority documents have been received.
    2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date 20030919.
- 4) Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: \_\_\_\_\_.

## DETAILED ACTION

### ***Status of Application, Amendments, And/Or Claims***

The Information Disclosure Statement (IDS) filed 19 September 2003 has been entered in full. Applicant's amendment of the specification filed 19 September 2003 has been entered. Applicant's amendment of the claims filed 5 December 2005 is acknowledged.

### ***Election/Restriction***

Applicant's election of Group I, claims 1-4, 15-17, 19 and 20, in the reply filed on 5 December 2005, and Applicant's election of species (c): KGF-2 fragments consisting of residues 65-208 of the amino acid sequence set forth in SEQ ID NO: 2 in the reply filed on 22 March 2006, are acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). Claims 5-14 and 18 have been cancelled. Claim 21 has been added. Claims 1-4, 15-17, 19-21 are pending and under examination.

### ***Specification***

The disclosure is objected to because of the following informalities:

The Application No: 09/284,100 is now patented. The first line of the specification should include updated cross-reference to related applications.

***Drawings***

The drawings/figures are objected to because tables and sequence listings included in the specification must not be duplicated in the drawings. See 37 C.F.R. §1.58(a) and §1.83. Applicants are advised that upon issuance of a patent, the complete text of the sequence listing submitted in compliance with 37 C.F.R. §§1.821-1.825 will be published as part of the patent. Applicants should amend the specification to delete any Figures which consist only of nucleic acid or protein sequences which have been submitted in their entirety in computer readable format (i.e. as SEQ ID NO.'s) and should further amend the specification accordingly to reflect the replacement of the Figure by the appropriate SEQ ID NO.:

Appropriate correction is required.

***Claim Objections***

Claim 1 is objected to because of the following informalities: Claim 1 recites non-elected inventions. Appropriate correction is required.

***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-4, 15-17, 19-21 are rejected under 35 U.S.C. 102(e) as being anticipated by Ruben et al. (U.S. Patent No: 6,077,692, which has a provisional filing date on 13 August 1996). The '692 patent teaches a KGF-2 polypeptide consisting of residues 65-208 of the KGF-2 protein (see Table in column 27), and having 100% identity to the KGF-2 fragment of the instant application (see sequence alignment). The '692 patent teaches that the KGF-2 polypeptide may have a Met residue at the N-terminus of the polypeptide (claims), and may be glycosylated or non-glycosylated, depending upon the host employed in a recombinant production procedure (column 37, lines 55-64). The '692 patent teaches a pharmaceutical composition comprising the KGF-2 polypeptide and a suitable pharmaceutical carrier (column 48, lines 57-65), and methods of making the KGF-2 polypeptide from a prokaryotic or eukaryotic host cell using recombinant technology (column 55-61, Examples 2, 3 and 4). The '692 patent teaches that the KGF-2 polypeptide may contain a water-soluble polymer (column 50, lines 3-65). The '692 patent also teaches that the KGF-2 polypeptide may be expressed as a fusion protein, such as fused with the constant region of the heavy chain of human immunoglobulin (column 36, lines 9-43). Therefore, the '692 patent anticipates the claimed invention.

***Conclusion***

NO CLAIM IS ALLOWED.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Xiaozhen Xie, Ph.D whose telephone number is 571-272-5569. The examiner can normally be reached on M-F, 8:30-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet L. Andres, Ph.D. can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



ELIZABETH KEMMERER  
PRIMARY EXAMINER

Xiaozhen Xie, Ph. D.  
April 7, 2006